BMRN BIOMARIN PHARMACEUTICAL INC
Company Analysis
Latest News
BioMarin Completes Acquisition of Alesta Therapeutics B.V.
BioMarin Pharmaceutical Inc. has announced the completion of its previously disclosed acquisition of Alesta Therapeutics B.V. The transaction, a share...
BioMarin Enters Global Patent Settlement with Ascendis Pharma for Royalty Payments
BioMarin Pharmaceutical Inc. has entered into a binding global settlement and license agreement with Ascendis Pharma A/S, resolving all pending patent-related...
Steve Cohen's Point72 Exits BioMarin (BMRN) Stake
Steve Cohen's Point72 Asset Management fully liquidated its position in BioMarin Pharmaceutical Inc. (BMRN) during the second quarter of 2026. The firm sold...
BioMarin to Acquire Alesta Therapeutics for up to $490 Million
BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Alesta Therapeutics B.V., a private Dutch company that develops oral small...
BioMarin second quarter 2026 revenue beats expectations on Amicus integration and raised 2026 guidance
BioMarin Pharmaceutical reported a significant top-line expansion in the second quarter of 2026, driven by the successful closing of the Amicus Therapeutics...
Biomarin Pharmaceutical Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts expect BioMarin Pharmaceutical to report Q2 2026 revenue of $931.3 million and non-GAAP EPS of $0.79, while the stock currently trades at $60.02, well...